NT-501 CNTF implant for Macular Telangiectasia

"According to the entrance requirements for this study, any person aged 18-85 is eligible to enroll."

"According to the latest update on clinicaltrials.gov, this study is no longer recruiting patients. This trial was initially posted on 8/13/2021 but has not been updated since 7/14/2022. There are, however, 24 other trials that may be of interest and are currently accepting participants."

"This particular clinical trial is seeking 30 individuals that have macular telangiectasia type 2. The participants must be between 18-85 years old and meet the following requirements: Be willing to comply with study procedures, sign an Informed Consent form, provide documentation of privacy consent, Must have completed the Month-24 visit for NTMT-03study , exit Phase 1/2 extension or Phase 3 study before entering Bilateral Implant safety study, Females of childbearing potential must take a pregnancy test, allow collection of blood samples for analysis in one eye, Have a positive diagnosis of MacTel type 2 in the study eye with evidence"

"The NT-501 CNTF implant received a 2 because, while there is data supporting its safety, none of the clinical trials thus far have looked at its efficacy."

"So far, 8 different medical centres have signed up to help with this clinical trial. This includes Retina Associates of Cleveland, Inc., Jules Stein Eye Institute in Los Angeles and Bascom Palmer in Miami - among other locations."